1134598-80-3

Upstream product

• 1134598-72-3 3-chloro-2-(3-methoxyphenyl)-3-pyridin-4-yl-acrylonitrile 
• 1134598-69-8 2-(3-methoxyphenyl)-3-oxo-3-pyridin-4-yl-propionitrile 
• 19924-43-7 3-methoxyphenylacetonitrile 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 1134598-74-5 4-[3-methoxy-phenyl]-5-pyridin-4-yl-1H-pyrazol-3-amine 

Downstream Products

• 1186421-43-1 3-[3-(3-hydroxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethylbenzenesulfonamide 
• 1186421-45-3 3-(3-(3-hydroxyphenyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-N-methylbenzenesulfonamide 
• 1186333-15-2 2-chloro-5-{7-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl}phenol 

Relevant academic research and scientific papers

BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Compounds of formula A: Formula (1) pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.

PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Phenylsulfonamide substituted, pyrazolo[1,5-a]pyrimidines are described. The compounds of the invention selectively inhibit Raf kinase activity and are useful for treating disorders associated with Raf kinases. Formula (I)

PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF

A pyrazolo[5,1-c][1,2,4]triazine compound of formula A: and pharmaceutically acceptable sats thereof. The multiply-substituted pyrazolo[5,1-c][1,2,4]triazine compounds of the invention selectively inhibit B-Raf kinase activity and are useful for treating disorders mediated by B-Raf kinase.